JPRN-UMIN000014104招募中3 期
Randomized phase III Study in patients with ANaplastic glioma of radiotherapy with Temozolomide versus nimustine hydrochloride(ACNU) followed by temozolomide (JCOG1016, SANTA study(P-III)) - (JCOG1016, SANTA study(Phase-III))
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 230 人开始时间: 2014年5月29日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 69years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancy, except for carcinoma in situ or mucosal tumors curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Active infectious meningitis 4) Body temperature >= 38 degrees Celsius at registration 5) Women during pregnancy, possible pregnancy, within 28 days after delivery, or breast-feeding 6) Psychosis or with psychotic symptom 7) Uncontrolled diabetes mellitus or routine administration of insulin 8) Unstable angina within 3 weeks, or with a history of myocardial infarction within 6 months 9) Interstitial pneumonia, fibroid lung, or severe lung emphysema 10) Gadolinium allergy 11) Positive HIV antibody 12) Potitive HBs antigen
研究者
相似试验
已完成
3 期
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189).10038666lung cancerNL-OMON50379Merck Sharp & Dohme (MSD)9
进行中（未招募）
1 期
Phase III study of Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC.non-squamous non-small cell lung cancerEUCTR2015-003694-15-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase III study of Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC.non-squamous non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 100000004864EUCTR2015-003694-15-BEMerck Sharp & Dohme LLC570
进行中（未招募）
1 期
Phase III study of Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC.EUCTR2015-003694-15-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase III study of Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC.EUCTR2015-003694-15-DKMerck Sharp & Dohme LLC570